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Abstract
Background: Because of their low levels of expression and the inadequacy of current research tools, CB2 cannabinoid
receptors (CB2R) have been difficult to study, particularly in the brain. This receptor is especially relevant in the context
of neuroinflammation, so novel tools are needed to unveil its pathophysiological role(s).
Methods: We have generated a transgenic mouse model in which the expression of enhanced green fluorescent
protein (EGFP) is under the control of the cnr2 gene promoter through the insertion of an Internal Ribosomal Entry Site
followed by the EGFP coding region immediately 3′ of the cnr2 gene and crossed these mice with mice expressing five
familial Alzheimer’s disease (AD) mutations (5xFAD).
Results: Expression of EGFP in control mice was below the level of detection in all regions of the central nervous system
(CNS) that we examined. CB2R-dependent-EGFP expression was detected in the CNS of 3-month-old AD mice in areas of
intense inflammation and amyloid deposition; expression was coincident with the appearance of plaques in the cortex,
hippocampus, brain stem, and thalamus. The expression of EGFP increased as a function of plaque formation and
subsequent microgliosis and was restricted to microglial cells located in close proximity to neuritic plaques. AD mice
with CB2R deletion exhibited decreased neuritic plaques with no changes in IL1β expression.
Conclusions: Using a novel reporter mouse line, we found no evidence for CB2R expression in the healthy CNS but
clear up-regulation in the context of amyloid-triggered neuroinflammation. Data from CB2R null mice indicate that they
play a complex role in the response to plaque formation.
Keywords: Cannabinoid CB2 receptor, Transgenic mice, Enhanced green fluorescent protein, Amyloid,
Neuroinflammation, Microglia
Background
It has been long appreciated that cannabinoids such as Δ9-
tetrahydrocannabinol (THC) exert effects on the immune
system [40]. A primary target for the cannabinoids to alter
immune system function, the cannabinoid receptor,
subtype 2 (CB2R), was identified molecularly in 1993
[23]. Autoradiographic and in situ hybridization studies
indicated a high level of expression of the CB2R in
cellular elements of the immune system but these
methods did not detect CB2R expression in the central
nervous system (CNS) [12, 18]. According to these
early data, the abundance of CB2R message in human
blood cells was highest in B-lymphocytes, followed by
natural killer cells, macrophages, and cluster of differ-
entiation (CD)8 and CD4 T-lymphocytes [12].
The presence of CB2Rs in the CNS has been the subject
of intense debate during the last decade. Some reports
[13, 35] showed the expression of CB2Rs in neuronal
elements of the uninjured brain, based primarily on im-
munohistochemical approaches. Other studies, however,
limited the presence of CB2R in the CNS to glial cells and,
specifically, to microglia [6]. Seminal studies by Cabral
and colleagues suggested that CB2R could be expressed by
microglial cells and that the expression level varied as a
function of cell activation [9]. Subsequent studies
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confirmed this hypothesis [19, 31]. Regarding human sam-
ples, we found expression of CB2R was restricted to peri-
vascular microglia in control brains [24] but that CB2R
protein were dramatically increased in different patho-
logical conditions. Observations made in Alzheimer’s dis-
ease (AD), multiple sclerosis, Down’s syndrome, and
immunodeficiency virus-induced encephalitis confirmed
that the presence of CB2R is greatly enhanced in areas of
neuroinflammation, predominantly in microglial cells (see
[6], for a review).
However, concerns regarding the lack of specificity
of antibodies against the CB2R protein have been
raised [3] (Additional file 1), which call into question
some of these results. It is clear that additional tools
are needed to unambiguously demonstrate the cellular
expression of CB2R throughout the body, but most
particularly within the CNS. We here introduce a
novel transgenic model designed to unveil the func-
tional distribution of cannabinoid CB2R and present
data regarding the expression of these receptors in
the mouse, with special attention to the CNS. Fur-
thermore, we used this new mouse model to analyze
the changes in the brain expression pattern of this re-





Mice were generated at Genoway facilities (Lyon, France).
A targeting strategy was designed consisting in the inser-
tion of an enhanced Green Fluorescent Protein (EGFP)
reporter gene, preceded by an Internal Ribosomal Entry
Site (IRES) sequence in the 3′ untranslated region (UTR)
of the cnr2 mouse gene. This approach results in the
expression of the reporter gene under the control of the
endogenous mouse cnr2 promoter and transcript from the
same bicistronic mRNA as the CB2R protein. Further, the
entire exon 3, including the 3′ UTR and knocked-in
reporter, is flanked by loxP sites, allowing the conditional
inactivation of the cnr2 gene in cells expressing Cre
recombinase (Fig. 1a).
Three isolated sequences encompassing the murine
cnr2 gene regions surrounding the targeted exon 3 were
used for the construction of the targeting vector. These





Fig. 1 Generation of a novel mouse model. a Genomic structure of the construct employed for the generation of CB2
EGFP/f/f and CB2
−/− mice. Hatched
rectangles represent cnr2 coding sequences, gray rectangles indicate non-coding exon portions, solid lines represent chromosome sequences. The
neomycin-positive selection cassette (Neo) IRES sequence and reporter gene (EGFP) are indicated. loxP sites are represented by blue triangles and FRT
sites by double red triangles. The initiation (ATG) and Stop (Stop) codons are indicated. For the generation of knock-in mice (CB2
EGFP/f/f), recombined
mice were bred with ubiquitous FLP-recombinase expressing mice, enabling the deletion of the FRT-flanked region. b For the generation of knock-out
mice (CB2
−/−), recombined mice were bred with ubiquitous Cre-recombinase expressing mice, resulting in the deletion of the loxP-flanked region. c
Representative Southern blot showing the expected wild-type (WT) and recombined (Rec) hybridization signals at 9302 and 5794 bp, respectively, in
embryonic stem cells from non-transfected (right column) and successfully transfected clones (left column). d Representative Western blot showing
EGFP expression in spleen tissue homogenates from CB2
EGFP/f/f (left lane) and CB2
−/− mice (right lane). e The basal expression level of CB2 receptor
mRNA is not modified as a consequence of the insertion of the genetic construct used for the generation of the knock-in mice (CB2
EGFP/f/f), as revealed
by qRT-PCR in spleen samples and comparison with WT mice
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containing exon 2 and downstream intronic sequences, (ii)
a 2980 bp-sized fragment containing the coding part of
exon 3 and upstream intronic sequences, and (iii) a
3657 bp-sized fragment containing the non-coding part of
exon 3 and downstream sequences. The linearized targeting
construct was transfected into C57BL/6J embryonic stem
cells. Homologous recombinant cells were identified by
Southern analysis and five clones were used to generate
chimeric mice. Chimeras were bred with C57BL/6J Flp-
and Cre-deleter females, in order to generate Neo-excised
EGFP reporter knock-in (CB2
EGFP/f/f ) mice (Fig. 1a) and
constitutive knock-out (CB2
−/−) mice (Fig. 1b), respectively.
Homozygous mice identified by PCR were further
verified by Southern blot analysis (Fig. 1c). All mice used
in this study were fourth- or fifth-generation offspring
from intercrosses of C57BL/6J mice. Mice were housed
and bred in the animal facilities of Universidad Rey Juan
Carlos (Alcorcón, Madrid, Spain) or the Medical College
of Wisconsin (Milwaukee, WI, USA). Experimental pro-
tocols met the European and Spanish regulations for
protection of experimental animals (86/609/EEC and RD
1201/2005 and 53/2013) or were approved by the Insti-
tutional Animal Care and Use Committee of the Medical
College of Wisconsin. Male mice were used in all experi-
ments included in the present report with the exception




Mice co-expressing five familial Alzheimer’s disease muta-
tions (5xFAD) were purchased from Jackson Laboratories
(Bar Harbor, ME, USA; [25]) on the C57BL/6J background
and were mated with CB2
EGFP/f/f and CB2
−/− mice and




employed in the present experiments were 3 to 6 months
old; this period was chosen based on previously published
data [25, 36] in order to allow for the appearance of
amyloid deposits.
Flow cytometry
Single cell suspensions were prepared from the spleens of
wild type, CB2
EGFP/f/f, and CB2
EGFP/f/+ mice of both sexes
as described previously [27]. Cells were incubated with
combinations of anti-mouse fluorescently-conjugated
antibodies as follows: anti-B220 PE, anti-CD4 APC-
eFluor780, anti-CD8 eFluor450, anti-CD11b eFluor450,
anti-CD11c PE, anti-Ly6C APC, anti-Ly6G APC/Cy7,
and anti-NK1.1 APC. Flow cytometry was used to identify
B cells (B220+CD4−CD8−), CD4 T cells (CD4+NK1.1−),
CD8 T cells (CD8+ NK1.1−), NKT cells (CD4+NK1.1+), NK
cells (CD4−NK1.1+), macrophages (CD11b+Ly6C+/−Ly6G−),
dendritic cells (CD11b+CD11chi), and granulocytes (CD
11b+Ly6C+Ly6G+). Sample acquisition was performed on a
BD Biosciences LSR II, and data was analyzed using FlowJo
software to generate the geometric mean of eGFP
expression in each immune cell population.
Immunofluorescence and neuritic plaque staining
Mice (N = 4–6 mice per group) were deeply anesthetized
and transcardially perfused with cold PBS (pH 7.4)
followed by freshly prepared cold 4% paraformaldehyde in
PBS (pH 7.4). Tissue samples were collected and post-
fixed in the same fixative overnight. Afterwards, tissues
were dehydrated by sequential transfer to 10 and 30% su-
crose solutions. Finally, tissues were cryoprotected with
Tissue-Tek and frozen in dry ice. Thirty-micrometer-
thick sections were obtained in a cryostat and pre-
served in cryoprotectant solution until use.
Floating tissue sections were washed with Tris Buffer
Saline (TBS) before overnight incubation at 4 °C with the
primary antibodies used for identification of the cellular
types. For EGFP identification, overnight incubation with
an anti-GFP antibody (1:1500; Abcam) was followed by in-
cubation with an Alexa 488 anti-chicken antibody conju-
gate (Invitrogen) carried out at 37 °C for 2 h, rendering
green fluorescence. Afterwards, sections were incubated
with a rabbit polyclonal anti-ionized calcium-binding
adaptor molecule 1 (Iba1) (1:1000 dilution, Wako, Osaka,
Japan), diluted in TBS containing 1% bovine serum albu-
min (BSA; Sigma, St. Louis, USA) and 1% Triton x-100
(Sigma). After the incubation, sections were washed in
TBS followed by incubation with an Alexa 546 anti-rabbit
antibody conjugate (Invitrogen, Eugene, OR, USA) at 37 °
C for 2 h, rendering red fluorescence. Additional tissue
sections were incubated with mouse monoclonal anti-
GFAP-Cy3 antibody (1:1500 dilution, Sigma) in the same
buffer for 2 h at 37 °C or with mouse monoclonal anti-
neuron-specific nuclear protein (NeuN) antibody (1:
1000 dilution, Merck Millipore, Darmstadt, Germany)
followed by incubation with Alexa 594 anti-mouse anti-
body conjugate (Invitrogen) as described above.
In order to study amyloid plaque deposits, a subset of
CB2
EGFP/f/f/5xFAD mice received an i.p. dose of 10 mg/
kg of methoxy-XO4 (a Congo Red derivative known to
selectively stain amyloid plaques; Tocris Bioscience; [4])
24 h prior to sacrifice. Brains were processed and sec-
tions were obtained and preserved for immunostaining
as described above.
Sections were mounted in aqueous solution (Vectashield,
Vector Laboratories, Burlingame, CA, USA), coverslipped,
and sealed. Slides were studied and photographed with up-
right microscopes (Nikon 90i, Nikon, Tokyo, Japan; and
Axioimager M2, Zeiss, Oberkochen, Germany) and using a
DXM1200F camera and C1 and LSM710 confocal systems
[36]. Image analysis was carried out as described [36] with
Metamorph (Molecular Devices, Sunnyvale, CA, USA) and
ImageJ software (Research Services Branch, National Insti-
tute of Mental Health, Bethesda, MD, USA).
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Western blotting
Protein fractions were collected from a Tri-pure extrac-
tion of hippocampal and spleen tissues, according to the
manufacturer’s instructions (Roche). Lysates (20 μg/lane
or 10 μg/lane for hippocampal and spleen protein sam-
ples respectively) were separated by SDS-PAGE and
transferred onto PVDF membranes (BioRad). After
blocking in Tris-Tween buffered saline (TTBS; 10 mM
Tris pH 7.5, 150 mM NaCl, 0.1% Tween 20 plus 5%
nonfat dried milk), they were incubated overnight at
4 °C, as appropriate, with anti-GFP (1:500, Abcam,
Cambridge, UK). Membranes were incubated with
corresponding horseradish peroxidase-conjugated sec-
ondary antibody (1:8000) and were developed using a
chemiluminescent reagent (ECL detection reagent
GE Healthcare, Buckinghamshire, UK). Developed
signals were recorded on X-ray film (Agfa) for densi-
tometric analysis (ImageJ, NIH, MD, USA). N = 4–6
mice per group were used for protein quantification
by Western blot.
ELISA Aβ1-42
Human ELISA kits (Invitrogen, Camarillo, CA, USA)
were used for the quantification of Aβ1-42 in the brain
soluble fractions, following the instructions provided by
the manufacturer. Levels were normalized to the total
amount of protein.
Real-time quantitative PCR for CB2 and IL1β
Total RNA was isolated using Tripure Isolation Reagent
(Roche, Mannheim, Germany) according to the protocol of
the supplier. RNA was dissolved in RNase-free water and
quantified by absorption at 260 nm. Aliquots were sub-
jected to 1% denaturing agarose gel electrophoresis and
GelRed Nucleic Acid Gel Stain (Biotium, Fremont, CA,
USA) staining to verify the quantity and quality of RNA.
Single-stranded complementary DNA (cDNA) was synthe-
sized from 1 mg of total RNA using LightCycler Taqman
Master (Roche Diagnostics). PCR primers and TaqMan
probes were designed by Tib Molbiol (Berlin, Germany)
(see Additional file 2: Figure S1). For normalization, 18S
primers and probe number 55 from Universal ProbeLi-
brary (Roche) were utilized. Gene expression was quanti-
fied using LightCycler FastStart DNA Master HybProbe
and LightCycler Taqman Master (Roche) and Quantimix
Easy Probes kit (Biotools, Madrid, Spain) in a LightCycler
thermocycler (Roche). The concentration of primers and
probes were 0.5 and 0.2 μM, respectively. PCR assays were
performed using 2 μl of the cDNA reaction. All assays were
carried out twice as independent PCR runs for each cDNA
sample. Mean values were used for further calculation. A
negative (no template) control was measured in each of
the PCR runs. Standard curves were calculated for quanti-
fication purposes using fivefold serial dilutions of cDNA
from mouse brain. The transcript amounts were cal-
culated using the second derivate maximum mode of
the LC-software version 4.0. The specific transcript
quantities were normalized to the transcript amounts
of the reference gene 18S. All further calculations and
statistical analyses were carried out with these values
referred to as relative expression ratios.
Statistics
Results are expressed as mean ± SEM. Statistical analysis
were made using student’s t test for comparisons between
two groups, analysis of variance (ANOVA), and two-way
ANOVA with Tukey’s post-test for multiple comparisons.
A p value < 0.05 was considered as statistically signifi-
cant (see Additional file 3: Table S1). Data were ana-
lyzed with Graph Pad Prism software version 6.0 (San
Diego, CA, USA).
Results
Basal expression of EGFP in CB2
EGFP/f/f mouse spleen is
coincident with previously described CB2 receptor
patterns of expression in immune cells
To characterize the newly generated CB2
EGFP/f/f mice, we
performed Western blotting on spleen samples. A single
band corresponding to the EGFP molecular weight was
evident in CB2
EGFP/f/f mice and was undetectable in spleen
samples from CB2
−/− mice (Fig. 1d). We determined
whether the strategy for the generation of the knock-in
mice modified the expression levels of CB2R gene.
Our results show that no changes were evident in
CB2R mRNA expression levels between WT and
CB2
EGFP/f/f mice in spleen (Fig. 1e; p = 0.474), thus
ruling out a putative impact of the transgene on basal
expression of the receptor.
We used flow cytometry to identify and quantify the
EGFP expression of splenocyte cell populations from
wild type, CB2
EGFP/f/+, and CB2
EGFP/f/f mice (Fig. 2a–c).
Using wild type mice, we found that background EGFP
immunofluorescence was low in all immune cell
populations examined (Fig. 2a). EGFP expression levels
in splenic immune cells were compared in heterozygous
(Fig. 2b) and homozygous (Fig. 2c) CB2
EGFP/f/f mice. In all
immune cell populations investigated, the homozygous
CB2
EGFP/f/f mice exhibited approximately double the mean
fluorescence intensity (MFI) of the heterozygous mice.
EGFP expression was highest in the B cell population,
which is consistent with reports that B cells have the
highest CB2 receptor expression among these cell types
[12]. Among the T cell populations, CD4 T cells and
NK T cells expressed a similar low level of EGFP
expression, while CD8 T cells expressed ~ threefold
higher levels (Fig. 2). NK cells expressed negligible
levels of EGFP (Fig. 2). Monocytes/macrophages and
dendritic cells expressed EGFP in a broader expression
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pattern than the lymphocytes (Fig. 2). Given that the
spleen contains numerous macrophage and dendritic
cell populations, it is likely that CB2R, and thus EGFP,
will be differentially expressed among them [7, 15].
Finally, of the myeloid subset, granulocytes exhibited the
highest amount of EGFP expression. These data are
consistent with the published reports of CB2R distribution
among these cell types [12] indicating that the CB2
EGFP/f/f
mouse is an excellent tool by which to determine steady
state CB2R expression in various spleen cell populations
using EGFP fluorescence.
We analyzed the expression of EGFP in spleens of
CB2
EGFP/f/f mice by immunofluorescence and found
discrete cell populations showing detectable signal.
EGFP+ B cells were detected, limited to the marginal
zone of the white pulp follicles, mostly located in the
follicular corona (Fig. 2d–f ).
Basal expression of EGFP in CB2
EGFP/f/f mice is
undetectable in the CNS but is induced as a consequence
of amyloid deposition
In the CNS, microscopic analysis of the brain and spinal
cord of 3-, 4-, or 6-month-old CB2
EGFP/f/f mice showed no
detectable EGFP immunoreactivity above background in
glial or neuronal elements of any region examined, which
included hippocampus (Fig. 3a), cortex, cerebellum,
thalamus, brain stem, and spinal cord (not shown). In
contrast, intense EGFP signal could be seen in brain
regions of CB2
EGFP/f/f/5xFAD mice known to be rich in
beta-amyloid neuritic plaques, such as hippocampus
(Fig. 3b). Other regions such as cortex, thalamus, and
brain stem also exhibited EGFP signal (data not
shown), in concordance with the previously reported
distribution of neuritic plaques [25]. EGFP+ cells
exhibited an ameboid shape and were mostly found in
clusters (Fig. 3c), suggesting they could be activated
microglial cells. No signal could be observed in the
hippocampus of CB2
−/−/5xFAD mice (Fig. 3d) or in any
other brain region examined (data not shown).
As shown in Fig. 3e, EGFP immunoreactivity above
background could be observed as early as 3 months
of age in the CB2
EGFP/f/f/5xFAD mice, and EGFP-
labeled cells increased in density with age in these
mice (Fig. 3e–h). EGFP+ were found in clusters throughout
the brain parenchyma and their distribution and increased
density with age paralleled that of neuritic plaques,
identified using methoxy-XO4, a dye for amyloid deposits
(Fig. 3i–l). Interestingly, no EGFP signal could be observed
in regions not exhibiting neuritic plaques (asterisks in
Fig. 3g–k). The number of EGFP+ cells was
dramatically increased at 4 and 6 months of age,
which also paralleled the increase in the appearance of
amyloid deposits (Fig. 3h: F3,18 = 58.46, p < 0.0001;
Fig. 3l: F3,23 = 64.70, p < 0.0001).
a b c
d e f
Fig. 2 EGFP presence and distribution in CB2
EGFP/f/ spleens determined using flow cytometry (a–c) and immunofluorescence (d–f). a–c Determination
of cell-specific expression of EGFP in splenocytes harvested from WT (a), CB2
EGFP/f/+ (b), and CB2
EGFP/f/f (c) mice. The numbers next to the histograms
are the mean fluorescence intensity (MFI). d–f CB2-dependent-EGFP expression in B-lymphocytes in the spleen of CB2
EGFP/f/f. EGFP expression was
evident in follicles of the white pulp. Scale bars, 100μm (d–g)
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CB2R induction is limited to plaque-associated microglial
cells
EGFP+ cells were located in association with neuritic
plaques (as revealed by staining with methoxy-XO4) and
exhibited morphological features of microglia (Fig. 4). Co-
localization studies with Iba-1, a commonly used marker of
cells of myeloid lineage, were carried out. Low magnifica-
tion (a to d) images showed a match in the pattern of distri-
bution among EGFP+ and Iba1+ cells in the subiculum of
6-month-old CB2
EGFP/f/f/5xFAD mice; in addition, our data
show that CB2-dependent EGFP expression takes place
selectively in Iba1+ cells located in the vicinity of neuritic
plaques (Fig. 4e–l). Microglial cells not associated with
these pathological structures showed no EGFP staining (see
Fig. 5a–d). For example, note the microglial cell at the
arrow in Fig. 5b is neither EGFP positive nor associated
with a plaque. Differences in the morphological features of
EGFP+ and EGFP− microglial cells were evident, with
EGFP+ cells exhibiting an ameboid-like shape (Fig. 5a
and b), typical of activated microglia, while EGFP− cells
showed a highly ramified morphology, characteristic of
quiescent, non-activated, microglia (arrow in Fig. 5b).





Fig. 3 In vivo EGFP induction in the context of AD, as revealed by immunofluorescence. a Un-manipulated, healthy CB2
EGFP/f/f mice showed no significant
EGFP signal in hippocampus (a). b, c EGFP signal could be noticed in the brain of CB2
EGFP/f/f/5xFAD mice; these cells showed ameboid shape. d No EGFP
signal could be observed in any brain region of CB2
−/−/5xFAD mice, including those enriched in amyloid plaques such as hippocampus. e–l EGFP signal in
CB2
EGFP/f/f/5xFAD mice increased with age and paralleled that of amyloid deposits. EGFP was evident in brain samples of CB2
EGFP/f/f/5xFAD mice starting at
3 months of age (e) and progressively increasing with age (4 months, f, and 6 months, g) and matched with the pattern of distribution of
amyloid-enriched plaques stained with methoxy-XO4 in those same samples (figure i–k). Note that neighboring brain regions devoid of
amyloid deposits exhibited a complete absence of EGFP signal (asterisks in g, k). h, l Densitometric quantification of EGFP+ cells (h) and
amyloid plaques (k) shows a parallel increase in neuritic plaques and EGFP expression. Data are expressed as mean ± SEM. *p < 0.05 vs
CB2
EGFP/f/f mice, # vs CB2
EGFP/f/f/5xFAD-3mo mice, and “a” vs CB2
EGFP/f/f/5xFAD-4mo mice. N = 5 for immunofluorescence labeling. Scale
bars, 10 μm (c) and 50 μm. DG (dentate gyrus); SBC (subiculum); CA1 (CA1 region of Ammon’s horn)
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Furthermore, we also studied whether other cell types in
the CNS, such as neurons or astrocytes expressed EGFP
in CB2
EGFP/f/f/5xFAD mice. To that end, co-localization
studies with a neuronal marker (NeuN; Fig. 5e–h) or with
a marker of astrocytes (GFAP; Fig. 5i–l) were carried out.
Our data indicate that neither of these cell types express
EGFP; thus, cnr2-dependent EGFP expression is limited to
microglial cells in CB2
EGFP/f/f/5xFAD mice.
Changes associated with CB2R deletion include decreases
in plaque deposition and no changes in gliosis or IL1β
expression
We analyzed the impact of cnr2 gene deletion on plaque
formation, soluble amyloid levels and neuroinflammation
(Fig. 6). We found a small but significant decrease in hippo-
campal neuritic plaque density (measured by staining with
methoxy-XO4; Fig. 6a: p < 0.0338) in the CB2
−/− mice that
was not paralleled by changes in soluble levels of Aβ1-42 in
the hippocampus (measured by ELISA; Fig. 6b: p < 0.6413).
Hippocampal microgliosis was assessed by counting Iba1+
cells in tissue sections. As expected, the 5xFAD mice
exhibited a significant increase in Iba1+ cells (Fig. 6c:
F1,23 = 85.84, p < 0.0001); however, there was no difference
in this measure between the wild type and CB2
−/− mice
(Fig. 6c: F1,23 = 0.03775, p = 0.8476). Finally, a significant
increase in interleukin-1 beta (IL1β) was observed as a
consequence of the amyloid pathology (Fig. 6d: F1,23 =
49.12, p < 0.0001) but CB2R genotype had no effect
(F1,33 = 0.2229, p = 0.6400).
Discussion
We have established a novel transgenic mouse model
(CB2
EGFP/f/f ) that allows for identification of cells that are
actively transcribing the cnr2 gene. The use of an IRES
allows for coupling of EGFP expression to cnr2 gene
transcription without loss or modification of the CB2
protein, which is a different approach from another
reporter mouse line in which the cnr2 gene is replaced by
EGFP, resulting in a CB2R knock out [29, 30]. The present
reporter mice are expected to provide crucial information
on the distribution, expression, and pathophysiological
roles of the CB2R, while maintaining its appropriate
cellular expression. By crossing these mice with 5xFAD
mice, we have expanded our knowledge regarding the
relevance of CB2R in amyloid pathology. The main
conclusions of this study are that, if CB2R are expressed
by neurons or glia in the CNS of healthy, un-manipulated
mice, they are expressed at very low turnover rates
a b c d
e f g h
i j k l
Fig. 4 Restricted EGFP expression in microglial cells located in peri-plaque areas of the CB2
EGFP/f/f/5xFAD mouse hippocampus. a–l Low-magnification
photographs of EGFP+ microglial cells (a, b) in close association to beta-amyloid neuritic plaques (c, d). Medium- (e–h) and high-magnification (i–l)
photographs of EGFP+ microglial cells. Detailed co-localization immunofluorescent analysis reveals a complete overlap between EGFP+ cells and Iba1+
cells, indicative of their macrophage/microglia nature, and a selective association to amyloid-enriched plaques (stained with methoxy-XO4). Scale bars,
100 μm (a–d), 25 μm (e–h), and 25 μm (i–l). SBC (subiculum)
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because no specific EGFP signaling could be detected in
any region of the mouse brain or spinal cord. Second,
under chronic neuroinflammatory stimuli (such as those
derived from the deposition of the amyloid peptide in the
brain parenchyma), the expression of CB2R is induced in
microglial cells, and this induction takes place specifically
in activated microglial cells surrounding neuritic plaques.
These data confirm and expand previously published lit-
erature and support the contention that the presence of
CB2R may be a diagnostic marker of neuroinflammation
in the context of AD [5, 6] and other pathological condi-
tions with a neuroinflammatory component [19, 20].
As previously suggested by us and by others [5, 19, 26],
the expression of CB2R is induced under neuroinflamma-
tory conditions in the human brain, being restricted to
microglial cells closely associated to foci of neuroinflam-
mation. Data obtained from samples of humans affected
by several neurodegenerative conditions with accompany-
ing neuroinflammation (i.e., AD, MS, HIV-encephalitis)
revealed a consistent pattern of CB2R induction in micro-
glia [6]. Our present data expand and confirm these obser-
vations. We used a well-known mouse model of amyloid
pathology (5xFAD) to calibrate the impact that the ap-
pearance of neuritic plaques in the brain parenchyma has
on the expression of CB2R. The analysis of CB2
EGFP/f/f/
5xFAD mice brain tissues showed that cnr2-dependent
EGFP expression is present in microglial (Iba1+) cells
located in the vicinity of amyloid-enriched neuritic pla-
ques (as revealed with methoxy-XO4 in vivo staining).
There was a remarkable lack of detectable EGFP expres-
sion in non-plaque areas. These data strongly support the
hypothesis that CB2R gene expression is increased primar-
ily in microglia that surround neuritic plaques.
The time-course of the appearance of neuritic plaques
in the subiculum of CB2
EGFP/f/f/5xFAD mice closely
matched that previously described [25, 36]. Importantly,
EGFP was detectable in plaque-associated microglia at
3 months of age, corresponding to the age when amyloid
deposits are first present in the brain parenchyma. These
data are indicative of the need to reach a threshold of
inflammatory stimuli in the cellular milieu before the
induction of CB2R expression takes place in the CNS.
The present data suggest that threshold is reached coin-
cident with appearance of the amyloid deposits. This
suggests (i) that the induction of the expression of CB2
receptors takes place after a period of sustained inflam-
mation and (ii) that CB2 receptors may be postulated as
early markers of AD pathology. In this sense, it is im-
portant to note that disease-linked symptoms in 5xFAD
mice are not evident before 6 months of age; thus, the
a b c d
e f g h
i j k l
Fig. 5 EGFP expression is limited to plaque-associated microglial cells but is absent in neurons and astrocytes in CB2
EGFP/f/f/5xFAD mice. a–c Z-stack
showing that EGFP expression (a) was evident in microglial cells (b) located in close association to amyloid-enriched neuritic plaques, as revealed by
methoxy-XO4 (c). However, microglial cells not linked with these pathological structures (arrow in b) showed reduced EGFP signal. d Orthogonal view
in Z axis of the cluster of microglial EGFP+ cells shown in (a–c). Note the intimate contact established by microglial processes into the neuritic plaque.
e–l Neurons (NeuN+ cells; e–h) nor astrocytes (GFAP+ cells; i–l) showed no EGFP signal. Scale bars, 25 μm
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induction of the cnr2 gene expression is previous to
phenotypic changes due to amyloid pathology, indicating
that CB2R may provide diagnostic and therapeutic tar-
gets for the treatment of early stage AD [28].
CB2R functions in microglia as well as in other types of
immune cells have been studied [8, 20]. In the context of
AD neuroinflammation, there is evidence that CB2R ago-
nists induce anti-inflammatory actions [1, 10, 21, 22, 26,
34], promote microglial migration and proliferation [37],
and enhance amyloid removal [33, 38]. Furthermore, there
is evidence that the activation of CB2R also decreases the
production of amyloid peptides in a mouse model of AD
[2], though conflicting results have been reported [29].
These effects make microglial CB2R interesting targets in
amyloid-induced neuroinflammation as microglia play
critical roles in the progression of the disease by modulat-
ing, for instance, amyloid removal, cytokine production or
exosome-mediated peptide degradation [14].
Surprisingly in light of earlier studies, CB2
−/−/5xFAD
mice exhibited a small but significant decrease in
neuritic plaque density in hippocampus compared to
wild type 5xFAD mice that was not accompanied by a
decrease in soluble Aβ1-42 levels, reduced microgliosis,
or changes in IL1β expression. We do not have a
conclusive explanation for this observation, though it is
suggestive of a role for CB2R in microglial functions related
to amyloid removal such as, for instance, phagocytosis [33].
In addition, conflicting results have been reported by
several groups regarding the consequences of CB2 deletion
on microgliosis, with both decreased and unchanged
microgliosis being reported [2, 16, 30]. Further experiments
are needed to clarify the reasons for these discrepancies
regarding the impact of CB2R deletion on the formation of
amyloid-enriched plaques.
Several recent studies indicate that CB2R agonists
affect neuronal function [11, 32, 39]. In particular, CB2R
Fig. 6 Consequences of CB2 deletion in the context of AD. The genetic inactivation of CB2 in CB2
−/−/5xFAD mice led to a significant decrease in
plaque density in hippocampus (a), without any changes in soluble amyloid production (b), or microgliosis (c). No changes were observed in the
expression of IL1β as a consequence of gene deletion (d) in CB2−/−/5xFAD mice as compared to those in CB2EGFP/f/f/5xFAD mice. Data are expressed
as mean ± SEM. *p < 0.05. Student’s t-test (a, b) and two-way ANOVA followed by Tukey’s post hoc test (c, d). N = 5 for immunofluorescence labeling
measurements and N = 6 for experiments on soluble amyloid quantification and IL1β expression
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agonists have been reported to affect hippocampal plas-
ticity, effects that are lost in CB2
−/− mice. These results
are difficult to reconcile in light of the lack of detectable
EGFP in the hippocampus of the present transgenic
mice and in another reporter model [29]. It is possible
that the turnover of the CB2R in neurons is slower than
the turnover of EGFP protein or the detectable amount
of EGFP expression may be lower than the CB2R
expression levels required to achieve a functional
response in vivo. Alternatively, it is possible that CB2R
expression is upregulated by the processes involved in
the preparation of tissues for study ex vivo.
Our data are discordant compared to those reported
in the Allen Mouse Brain Atlas [17]. Information pro-
vided by this platform reveals low but detectable levels
of CB2-mRNA in olfactory and cortical subplate areas,




showed specific EGFP signal in either of these regions.
We do not have an explanation for this discrepancy
other than the mentioned mismatch between detection
limits, in this case referred to single cell-ISH (Allen
Atlas) and EGFP immunostaining (present data).
Conclusions
In summary, the present findings confirm and expand
previous data showing the selective induction of CB2R in
neuritic plaque-associated microglia and postulate these
receptors as diagnostic and therapeutic targets in AD.
The newly developed transgenic mouse model will be in-
strumental for elucidating their role(s) in neuroinflam-
matory conditions.
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